Table 3.
Determinants of progression-free survival after BCNU treatment of recurrent glioblastoma (n = 34, 30 events)
| Hazard ratio* | 95% confidence interval | p-value | ||
|---|---|---|---|---|
| Age (years) | ≤ 53 vs. > 53 (the median) | 1.12 | 0.41-2.98 | 0.844 |
| Tumor size (mm2) | ≤ 736 vs. > 736 (the median) | 0.46 | 0.15-1.42 | 0.177 |
| not measurable vs. > 736 | 0.45 | 0.16-1.28 | 0.135 | |
| Karnofsky performance score | ≤ 70 vs. 80 or 90 | 0.50 | 0.20-1.26 | 0.143 |
| Surgery | Complete resection vs. biopsy/partial resection | 3.11 | 1.02-9.52 | 0.047 |
| Pre-treatment with temozolomide | yes vs. no | 1.30 | 0.43-3.91 | 0.641 |
| Previous relapses | 1 vs. more than 1 | 0.48 | 0.14-1.61 | 0.232 |
* A hazard ratio <1 (>1) indicates an effect in favor of the first (the second) group in terms of progression-free survival.